Letrozole
NDC Package 0179-0169-70

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Letrozole is a medication used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Marketed by Kaiser Foundation Hospitals, this product is identified by NDC 0179-0169 and is authorized under FDA application ANDA090934.

Identification & Billing

NDC Package Code
0179-0169-70
Package Description
30 TABLET, FILM COATED in 1 BOX, UNIT-DOSE
Product Code
0179-0169
11-Digit Billing Format
00179016970

Clinical Specifications

Proprietary Name
Letrozole
Dosage Form
-
Usage Information
This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Regulatory & Marketing

Labeler Name
Kaiser Foundation Hospitals
FDA Application #
ANDA090934
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
02-05-2015
End Marketing Date
09-30-2018
Listing Expiration
09-30-2018
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0179-0169-70 identifies a specific commercial package of 30 tablet, film coated in 1 box, unit-dose of Letrozole, labeled by Kaiser Foundation Hospitals. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Kaiser Foundation Hospitals on February 05, 2015. The current certification is valid through September 30, 2018.

What are the primary indications for this medication?

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

How is this Kaiser Foundation Hospitals product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00179016970. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0179-0169-70
11-Digit CMS (5-4-2)
00179-0169-70

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.